Relationships between midembryonic 5-HT2 agonist and/or antagonist exposure and detour learning by chickens.
The importance of serotonin (5-HT) as both a transmitter and a regulatory signal during development of many species is well established. The availability of 5-HT receptor subtype agonists and antagonists will enable pharmacological dissection of the importance of one or more of the 5-HT receptors for their involvement in the mediation of developmental insults by drugs that are less selective but include actions upon serotonergic function. Such insults include exposure to cocaine or opiate withdrawal, both of which are blocked or attenuated by 5-HT2 antagonists. The 5-HT2 receptor agonist dimethoxyiodophenylaminopropane (DOI), like cocaine, causes vasoconstriction during embryogenesis, herniated umbilici in hatchlings, and altered detour learning by young chickens after injection into eggs at late stages of embryogenesis. The 5-HT2 antagonist ritanserin (RIT) blocks or significantly attenuates these effects. This study describes an effect of DOI on posthatch detour learning when injected earlier during embryogenesis (i.e., on embryonic day 12, E12) which is opposite its effect when injected later (i.e., on E15). Both effects are blocked by an inactive dose of RIT (0.3 mg/kg egg) and by a higher dose of RIT (0.9 mg/kg egg), which itself retards posthatch detour learning following E12 injection. Thus, excessive stimulation or blockade of 5-HT2 receptors around midembryogenesis can cause a similar behavioral teratogenic outcome. The data are discussed in relation to the likelihood that potential use of 5-HT2 antagonists for treating pregnant women and their fetuses who are not at risk is nil.
Bollweg
G
G
Department of Pharmacology, University of Minnesota, Minneapolis 55455, USA.
Sparber
S B
SB
D000662:Amphetamines / Q000008:administration & dosage / Q000633:toxicity; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002642:Chick Embryo; D002645:Chickens / Q000502:physiology*; D005260:Female; D006801:Humans; D007858:Learning / Q000187:drug effects* / Q000502:physiology; D009043:Motor Activity / Q000187:drug effects; D011247:Pregnancy; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D016713:Ritanserin / Q000008:administration & dosage / Q000633:toxicity; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000633:toxicity*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000633:toxicity*; D013997:Time Factors
D000662:Amphetamines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D016713:Ritanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine